Pioglitazone dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Pioglitazone is an approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
Evidence grade for Pioglitazone: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 2 completed trials, 9,114 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 9,114
- Human studies
- 2
- Found nothing
- 1
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use.
5 effects reported, 4 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Heart and circulation, Bone and joints
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Pioglitazone is a prescription diabetes pill. It makes your body more sensitive to insulin. It has real heart and stroke trials behind it. It also has real downsides.
What people take it for
- Better blood sugar in type 2 diabetes.
- Less liver fat.
- A longer life, on the idea that better insulin use slows ageing.
What studies in people showed
In 3,876 people with insulin resistance who had just had a stroke, fewer had another stroke or heart attack. It was 9.0 percent against 11.8 percent over about five years. New diabetes was about halved. But more people gained weight, had swelling and broke bones. In 5,238 people with diabetes and artery disease, it missed its main goal. More went to hospital with heart failure. Now mice. It did not help either sex live longer. Female mice died sooner.
What people report
Reports, not study results
The good
- It reliably lowers blood sugar in type 2 diabetes.
The bad
- Weight gain of more than 4.5 kg in about half of people in the stroke trial (52.2 percent against 33.7 percent).
- Swelling (35.6 percent against 24.9 percent in the stroke trial).
- More broken bones, clearest in women.
- A higher risk of heart failure. It carries the FDA's strongest warning for that.
Where these come from: The side effects are from the stroke and diabetes trials and the drug warnings on this page. We have no user reports.
My bottom line
A real diabetes drug with real trade-offs. As a longevity pill it failed, and it hurt female mice. Leave it to your doctor for diabetes.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Pioglitazone has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Heart attacks and strokes9,114 people · 2 studies · 1 found nothing
- Bone strength3,876 people · 1 study
- Living longer3,876 people · 1 study
33 of the 36 indexed goals have no study of any kind behind Pioglitazone
No study in people, animals or cells on this page reports a result for these. That does not prove Pioglitazone does nothing for them. It does mean anything you have heard about Pioglitazone and one of these did not come from a study cited here.
Show full evidence
What is Pioglitazone?
Pioglitazone is an approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
Pioglitazone is an unusual entry. Its human record is strong and its ageing record is negative, and both need saying together.
In people, it is an approved diabetes pill that makes the body more sensitive to insulin. It has a real trial behind it that tracked heart attacks and strokes, which most things on this site do not. It also has well-known harms: water retention, weight gain, a higher risk of heart failure, and a higher risk of broken bones, especially in women.
In the mouse lifespan program it failed, and worse than failed. Of the eleven compounds in the 2026 run, pioglitazone was one of two whose harm to female lifespan held up after leaving out a lab with unusually long-lived untreated mice. A summary of the results recorded a drop of about 9.4 percent in typical (median) female lifespan.
Anyone treating a drug of this type, one that switches on PPAR-gamma, as a way to live longer should read that result first.
How does Pioglitazone work?
Pioglitazone switches on PPAR-gamma, a control switch inside cells found mostly in fat tissue. That makes new small fat cells that respond well to insulin. It moves fat out of the liver and muscle, and lowers free fatty acids in the blood. That is how it makes the whole body more sensitive to insulin. The same switch makes the kidney hold on to salt, which causes the swelling and the heart failure risk. It also pushes stem cells in the bone marrow to become fat instead of bone, the likely route to the broken bone risk.
What have studies in people found about Pioglitazone?
Lots. Pioglitazone is an approved drug with decades of use, big trials that tracked real health events, and well-known harms. None of that human evidence is about ageing or lifespan.
- In 5,238 people with diabetes and artery disease (PROactive), it missed its main goal. A narrower measure of deaths, heart attacks and strokes was lower (301 against 358 people). Hospital stays for heart failure were 6 percent against 4 percent.
- In 3,876 people without diabetes who had insulin resistance and a recent stroke or mini-stroke (IRIS), another stroke or heart attack hit 9.0 percent on the drug against 11.8 percent on a dummy pill over about five years. New diabetes was about halved. Deaths were about the same. Weight gain, swelling and broken bones were more common.
- Approved for type 2 diabetes. It reliably improves insulin sensitivity and blood sugar.
- Carries the FDA's strongest (boxed) warning for heart failure, caused by salt and water retention.
- Weight gain and swollen legs are common and expected, not rare.
- A higher risk of broken bones, clearest in women, is on record. It fits with what the drug does in bone marrow.
- It lowers liver fat, which is why it keeps coming up in fatty liver research.
- No human trial has tested it for anything to do with ageing.
What this does not tell you: The human record shows this drug treats diabetes and has specific risks. It says nothing about healthy years or lifespan. The only careful lifespan test found no benefit, and a harm signal in females. Jumping from better insulin sensitivity to a longer life is exactly the leap the mouse data goes against.
The state of the research
This compound was one of eleven in the program's run reported in 2026. None of the eleven clearly made male or female mice live longer. The run is worth seeing as a whole. It deliberately retested astaxanthin, mitoglitazone and meclizine. The same program had earlier found all three made mice live longer. This time they were given at different doses or started at older ages, and all three failed. In females, pooling all three labs, astaxanthin, late-start mitoglitazone and pioglitazone were linked to clearly shorter lives. A closer look found that untreated females at one lab lived unusually long. With that lab left out, the harm held for mitoglitazone and pioglitazone only. The authors conclude that timing and dose matter a great deal, and that results from one lab or one run need careful reading.
Pioglitazone matters more than the other failures in that run, because the reason to test it was good. Insulin sensitivity tracks with long life across species. Eating less improves it, and part of metformin's ageing case rests on it. If better insulin sensitivity made animals live longer, this drug should have done it. It did not, and in females it went the other way.
The National Institute on Aging runs the Interventions Testing Program at three separate labs: The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a mixed breed made by crossing four strains, so a result cannot be a quirk of one strain. Compounds go in the food. Both sexes are tested. Each group is big enough to spot about a 10 percent change in lifespan. Results are checked with one test for typical lifespan and another for the longest-lived mice. The failures are published next to the wins. No other ageing research has all of that together. That is why a no from this program means much more than a no from one lab.
The evidence, in charts
Fig. 1a · how many people
9,114people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| The Lancet 2005 | 5,238 | 57% |
| IRIS, The New England Journal of Medicine 2016 | 3,876 | 43% |
One study holds 57% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Animal study · done in animals133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2005 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 356.4 Da. A small molecule, not a peptide.
- Half-life
- About 20 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: Three to seven hours for the parent compound, with active metabolites extending to roughly 16 to 24 hours, which supports once-daily dosing.
No amino acid sequence is on file for Pioglitazone, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2005Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
The big heart outcomes trial of pioglitazone in diabetes missed its main target. A wide measure of heart and artery events was not clearly lower. A narrower measure of deaths, heart attacks and strokes was lower. More people on the drug went to hospital with heart failure. These were people with diabetes and existing artery disease.
5,238 patients with type 2 diabetes and macrovascular disease randomised to oral pioglitazone titrated from 15 to 45 mg or matching placebo on top of usual treatment, mean follow-up 34.5 months. Missed its primary endpoint: the broad composite occurred in 514 versus 572 patients (HR 0.90, 95% CI 0.80 to 1.02, p=0.095). The main secondary composite of death, non-fatal myocardial infarction and stroke occurred in 301 versus 358 (HR 0.84, p=0.027). Hospital admission for heart failure 6% versus 4%.
- Study in people2016Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
In people with insulin resistance but no diabetes who had just had a stroke or a mini-stroke, pioglitazone lowered the chance of another stroke or a heart attack over about five years. It also halved new diabetes. It cost more weight gain, swelling and broken bones. Death rates were about the same.
3,876 patients without diabetes, with insulin resistance and a recent ischaemic stroke or TIA, randomised to pioglitazone (target 45 mg daily) or placebo, median 4.8 years (IRIS). Stroke or myocardial infarction in 9.0% versus 11.8% (HR 0.76, 95% CI 0.62 to 0.93, p=0.007). Diabetes in 3.8% versus 7.7% (HR 0.48). All-cause mortality similar (HR 0.93). Weight gain over 4.5 kg 52.2% versus 33.7%, oedema 35.6% versus 24.9%, fracture needing surgery or hospitalisation 5.1% versus 3.2%.
- Animal study2026Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan
In mice. The NIA mouse lifespan program tested eleven compounds at three labs. None clearly made male or female mice live longer. In females, pooling all labs, astaxanthin, late-start mitoglitazone and pioglitazone were linked to clearly shorter lives. With one lab left out, where untreated females lived unusually long, the harm held for mitoglitazone and pioglitazone only.
Interventions Testing Program, eleven compounds in UM-HET3 mice across three sites. None significantly increased lifespan in male or female mice. In females, pooling all sites, astaxanthin, late-start mitoglitazone and pioglitazone were associated with significantly reduced lifespan. After excluding one site whose control females lived unusually long, the negative effect remained for mitoglitazone and pioglitazone only.
Common questions
Has Pioglitazone been tested in people?
Yes. 9,114 people given it across 2 completed trials cited here, 1 of which found nothing. Pioglitazone is an approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
What is the Pioglitazone dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use.
Is Pioglitazone FDA-approved?
FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use.
Does pioglitazone extend lifespan?
No. In the only careful lifespan test run at several labs, it did not make male or female mice live longer. In females it was linked to clearly shorter lives, in the check that held up after leaving out an odd lab. There is no human lifespan data.
Should I take it for insulin resistance if I do not have diabetes?
That is a question for a prescriber. The facts that matter: it does improve insulin sensitivity. It carries the FDA's strongest warning for heart failure. It causes weight gain and water retention, and it raises the risk of broken bones in women. The ageing case that might have made those risks worth it is not backed by the lifespan data.
Why does a diabetes drug appear in a longevity database?
Because the National Institute on Aging formally tested it as a way to live longer, and it failed. A compound tested and found not to work tells you more than one nobody has tested, and almost nobody publishes that.
Latest reading on Pioglitazone
Blog posts about Pioglitazone, newest first.